Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017132620) METHODS AND COMPOSITIONS USING INTEGRIN-BASED THERAPEUTICS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/132620 International Application No.: PCT/US2017/015506
Publication Date: 03.08.2017 International Filing Date: 27.01.2017
IPC:
C07K 14/78 (2006.01) ,C07K 16/28 (2006.01) ,C12N 15/12 (2006.01) ,A61K 38/17 (2006.01) ,A61K 39/395 (2006.01) ,A61K 31/7088 (2006.01) ,A61P 29/00 (2006.01) ,A61P 37/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
78
Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
12
Genes encoding animal proteins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
Applicants:
LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY [US/US]; 9420 Athena Circle La Jolla, California 92037, US
Inventors:
LEY, Klaus; US
Agent:
HO, Patrick; US
Priority Data:
62/288,76129.01.2016US
Title (EN) METHODS AND COMPOSITIONS USING INTEGRIN-BASED THERAPEUTICS
(FR) MÉTHODES ET COMPOSITIONS UTILISANT DES PRODUITS THÉRAPEUTIQUES À BASE D'INTÉGRINE
Abstract:
(EN) The present invention is directed to modified integrin proteins and methods and compositions using integrin-based therapeutics. In one embodiment, the modified integrins demonstrate increased occurrence or duration of the E-H+ integrin protein conformation. In another embodiment, the compounds of the present invention stabilize E-H+ integrin protein conformation, increasing the occurrence or duration of the E-H+ integrin protein conformation. In another embodiment, the compounds of the present invention inhibit binding of a ligand of an integrin. In yet a further embodiment, the present compounds increase cis binding of the integrin or signaling based thereon. The present compounds decrease the occurrence or duration of trans binding of the integrin or signaling based thereon. The modified integrins and compounds described herein may be used in methods of treating immune modulated diseases or inflammatory diseases or conditions.
(FR) La présente invention concerne des protéines d'intégrine modifiées et des méthodes et des compositions utilisant des produits thérapeutiques à base d'intégrine. Dans un mode de réalisation, les intégrines modifiées révèlent une augmentation de l'occurrence ou de la durée de la conformation E-H+ de la protéine d'intégrine. Dans un autre mode de réalisation, les composés de la présente invention stabilisent la conformation E-H+ de la protéine d'intégrine, augmentant ainsi l'occurrence ou la durée de la conformation E-H+ de la protéine d'intégrine. Dans un autre mode de réalisation, les composés de la présente invention inhibent la liaison d'un ligand d'une intégrine. Dans encore un autre mode de réalisation, les composés de l'invention augmentent la liaison cis de l'intégrine ou la signalisation basée sur celle-ci. Les composés de l'invention diminuent l'occurrence ou la durée de la liaison trans de l'intégrine ou la signalisation basée sur celle-ci. Les intégrines modifiées et les composés décrits dans la présente description peuvent être utilisés dans des méthodes de traitement de maladies à modulation immunitaire ou de maladies ou d'états pathologiques inflammatoires.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
US20180369330